Fig. 6: Measurement of clenbuterol levels in tissue and plasma of mice and rats. | npj Parkinson's Disease

Fig. 6: Measurement of clenbuterol levels in tissue and plasma of mice and rats.

From: Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

Fig. 6: Measurement of clenbuterol levels in tissue and plasma of mice and rats.

Tissue from the hippocampus, and plasma from mice and rats in the 1 day and 1-week paradigms were collected. Tissue was treated to separate the clenbuterol (clen) that was and was not interacting with proteins, producing a bound and unbound clenbuterol fraction respectively. Bound clenbuterol in a rats and b mice. Unbound clenbuterol in the c rat and d mice. Total clenbuterol in the plasma from e rats and f mice. Columns indicate the group means, circles represent individual data points (n = 5 per group), error bars represent ±1 standard error of the mean. A line connecting columns indicates significance between groups (p ≤ 0.05).

Back to article page